Petroleo Brasileiro SA (Petrobras) PBR – Recap
Yesterday morning, one of the primary focal points our premarket report was a pair of PBR options contracts, the PBR Weekly $14 & 14.50 Calls.
We cited the stock’s volatility and rapid rise over recent relative lows as the reasons for our interest, and despite yet another reversal for the markets in general, we got very solid single-session results for our PBR ideas. The $14’s traded up 95% from .21-.41, while the $14.50’s logged a double-bagger as they ran from .05-.11, a gain of 120%
PBR is gapping up once again this morning, so we expect these figures to open up even higher. We will then be looking for a possible dip-and-rip scenario.
BioXcel Therapeutics, Inc. BTAI
We mentioned BTAI for the first time in yesterday morning’s extended watchlist, and got a solid first day performance from that stock as well, as it went in the books as the 2nd highest gainer on the Nasdaq for the session.
From a low of 4.00, BTAI went on to hit a high of 5.84, which worked out to a respectable 46% rise that also bucked the overall trend of the day. The move was facilitated by news that the company achieved positive human proof-of-concept data for acute treatment of agitation in patients with Alzheimer’s Disease, and other degenerative neural disorders. (>>View PR)
W, APU, ARGX, MYSZ, SN, XPO, EPZM, AMID, PROP, SING